Review
Version 1
This version is not peer-reviewed
Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer
Version 1
: Received: 25 July 2024 / Approved: 26 July 2024 / Online: 26 July 2024 (12:58:56 CEST)
How to cite: Pergolizzi, R. G.; Brower, S. Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer. Preprints 2024, 2024072126. https://doi.org/10.20944/preprints202407.2126.v1 Pergolizzi, R. G.; Brower, S. Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer. Preprints 2024, 2024072126. https://doi.org/10.20944/preprints202407.2126.v1
Abstract
Pancreatic cancer is one of the most aggressive and lethal forms of cancer, with a five-year survival rate of less than 10%. Despite advances in treatment modalities, the prognosis for pancreatic cancer patients remains poor, highlighting the urgent need for innovative approaches for early diagnosis and targeted therapies. In recent years, there has been significant progress in understanding the molecular mechanisms underlying pancreatic cancer development and progression. This paper reviews the current knowledge of molecular targets for the diagnosis and treatment of pancreatic cancer.
Keywords
PC (pancreatic cancer]); driver mutations; miRNA
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment